Kempen & Co acted as Lead Manager in Galecto’s Initial Public Offering on the Nasdaq Global Select Market, successfully raising USD 85.0 million
Galecto is a clinical stage biotechnology company with advanced programs in fibrosis and cancer centered on galectin-3 and LOXL2. The Company’s pipeline includes an inhaled galectin-3 modulator currently in Phase IIb for the potential treatment of idiopathic pulmonary fibrosis, as well as two assets about to move into Phase II targeting NASH and myelofibrosis. The Company is incorporated in the U.S. and has its operating headquarters in Copenhagen, Denmark.
In 2020, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include: